The analgesic and anti-inflammatory profile of (+/-)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2a]pyrrole-1-carboxylic acid (RS-37619)

Agents and Actions
W H RooksM E Schuler

Abstract

RS-37619 showed highly potent analgesic activity when given p.o. in tests utilizing underlying inflammation. It inhibited phenylquinone-induced writhing in the mouse and rat (350 and 180 x aspirin respectively) and the pain induced by flexing the adjuvant-inflamed rat paw (approximately 800 x aspirin). The agent increased the pain threshold of compressed yeast-inflamed rat paws (3-10 x naproxen). RS-37619 did not increase the pain threshold of the non-inflamed paw and was inactive in the mouse hot plate test; therefore it is probably not a centrally acting or morphine-like agent. RS-37619 was also highly active p.o. in rat models of acute and chronic inflammation. It inhibited carrageenan-induced paw edema (36 x phenylbutazone), cotton pellet-induced granuloma (less than or equal to 1 x indomethacin) and in an 18-day test, prevented the development of adjuvant-induced arthritis (approximately 2 x naproxen). RS-37619 exhibited antiphlogistic activity in adrenalectomized rats. It did not have corticosteroid activity. When given p.o., RS-37619 lowered yeast-induced pyrexia (20 x aspirin). Gastrointestinal irritation was seen in the rat with doses greater than or equal to 6.4 mg/kg/day p.o. The agent elicited mild CNS and cardiovas...Continue Reading

References

Jun 1, 1975·Chemical & Pharmaceutical Bulletin·S Kuzuna, K Kawai
Jan 1, 1956·Proceedings of the Society for Experimental Biology and Medicine·C M PEARSON
Dec 1, 1962·Proceedings of the Society for Experimental Biology and Medicine·C A WINTERG W NUSS

❮ Previous
Next ❯

Citations

Jan 1, 1994·British Journal of Clinical Pharmacology·P J HayballR L Nation
Aug 23, 2002·Acta Anaesthesiologica Scandinavica·Y W HuangL C Yang
Sep 7, 2007·Journal of Veterinary Pharmacology and Therapeutics·R NagillaW R Ravis
Nov 1, 1990·DICP : the Annals of Pharmacotherapy·B H Resman-Targoff
Nov 1, 1988·The Journal of International Medical Research·O VangenE Lindbaek
Jun 1, 1995·The Journal of Pharmacy and Pharmacology·V Granados-SotoF J López-Muñoz
Jan 24, 2009·Journal of Veterinary Pharmacology and Therapeutics·R NagillaW R Ravis
Jan 7, 2015·Critical Reviews in Analytical Chemistry·Monika WieczerzakJacek Namieśnik
Jul 1, 1992·The Annals of Pharmacotherapy·J T MossS Sayson
Dec 22, 1999·Journal of Veterinary Pharmacology and Therapeutics·K PasloskeP Conlon
Sep 1, 1986·Pharmacotherapy·S S BloomfieldJ P Yee
Jan 1, 1988·Journal of Ocular Pharmacology·E B Fraser-Smith, T R Matthews
Jun 1, 1996·Journal of Clinical Pharmacology·E MroszczakL Depass
Mar 8, 2011·European Journal of Drug Metabolism and Pharmacokinetics·Ravindranath Reddy GilibiliNuggehally R Srinivas
Apr 29, 1998·Journal of Clinical Pharmacology·D A HandleyJ R McCullough
Sep 30, 2015·Journal of Veterinary Pharmacology and Therapeutics·A W BiancoS D Taylor
Jun 11, 2017·Journal of Veterinary Pharmacology and Therapeutics·A W BiancoS D Taylor
Aug 12, 2009·Expert Opinion on Drug Delivery·V R SinhaG Singh
Apr 3, 2021·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Joanne Shalini Chewa RajaFazliana Ismail
Nov 1, 1988·Immunopharmacology·E B Fraser-Smith, T R Matthews

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.